Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADIPOA2

Financiado

Cerrado

Clinical trial of autologous adipose derived mesenchymal stromal cells ASC in...

Clinical trial of autologous adipose derived mesenchymal stromal cells ASC in the treatment of mild to moderate osteoarthritis Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to prevent disease progression. Currently, OA is designated the 11th highest contributor (of 291 d... ver más

31/12/2019

OLLSCOIL NA GAILLI...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 22 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-31

PHC-15-2014: Clinical research on regenerative m...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

22 Participantes

OLLSCOIL NA GAILLIMHE

1.09M€ | Lider

ISOTROL

1.38M€ | Participante

CNRS

165.21K€ | Participante

EWK Spandau

246.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

REGENER-AR Bringing Regenerative Medicine into the market Allogeneic e... 8M€ Cerrado

ADIPOA ADIPOSE DERIVED STROMAL CELLS FOR OSTEOARTHRITIS 12M€ Cerrado

AutoCRAT Automated Cellular Robot Assisted Technologies for translati... 7M€ Cerrado

NeoCellBank A revolutionary regenerative therapy for management of chron... 71K€ Cerrado

RESSTORE REgenerative Stem cell therapy for STroke in Europe 6M€ Cerrado

MAXIBONE Personalised maxillofacial bone regeneration 6M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2014-12-01
Fecha Fin: 2019-12-31

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to prevent disease progression. Currently, OA is designated the 11th highest contributor (of 291 diseases) of global disability. In the absence of effective treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential candidates to overcome this clinical short-coming. Autologous adipose-derived mesenchymal stromal cells (ASCs) are attractive for cellular therapy given the abundance of tissue, high frequency of MSCs and minimally invasive harvest procedure. The EU consortium ADIPOA has shown in a ‘first in man’ 2-centre Phase I safety study that intraarticular injection of a single dose of autologous ASCs to the knee (18 patients, 12 month follow-up) was well-tolerated, had no adverse effects, and resulted in an improvement in pain score and functional outcome. ADIPOA2 will deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. ADIPOA2 will comprise a multi-centre, randomized clinical trial comparing culture-expanded, autologous adult ASCs in subjects with knee OA with another widely used therapeutic approach for knee degeneration (injection of Hyaluronan). There are two large elements of the study: (1) the production of consistent batches of high-quality autologous ASCs under GMP-compliant conditions and (2) delivery of these cell doses to patients in a trial which will meet all national and European regulatory and ethical standards and which will have sufficient statistical power to provide an unambiguous and definitive assessment of safety and efficacy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores